Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for Allergic Rhinitis Symptoms
NCT06806826Phase 4Completed
- Sponsor
- Van Yuzuncu Yil University
- Start
- Jan 2019
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of omalizumab in allergic rhinitis (AR), sponsored by Van Yuzuncu Yil University. Started Jan 2019; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06806826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06806826.